• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鼻中隔癌

Carcinoma of the nasal septum.

作者信息

LeLiever W C, Bailey B J, Griffiths C

出版信息

Arch Otolaryngol. 1984 Nov;110(11):748-51. doi: 10.1001/archotol.1984.00800370050012.

DOI:10.1001/archotol.1984.00800370050012
PMID:6487127
Abstract

Twenty-two patients with nasal septal carcinoma have been treated at the University of Texas Medical Branch, Galveston, during the 18-year period from 1961 to 1979. Squamous cell carcinoma of the nasal septum was found in 18 patients (82%), with single instances of reticulum cell sarcoma, basal cell carcinoma, histiocytic lymphoma, and transitional cell carcinoma. One of the squamous cell carcinoma group had palpable cervical metastasis at diagnosis, with metastatic neck disease developing in eight patients from three to 25 months after treatment. Squamous cell carcinoma of the nasal septum is aggressive and often undertreated. Our experience suggests that patients with septal carcinoma of any size should be treated by wide surgical excision (via lateral rhinotomy) and irradiation to the primary site and neck. Control of the primary tumor was achieved in 17 of 18 patients, with neck control in ten patients. The five-year absolute survival rate for squamous cell carcinoma of the nasal septum was 66%.

摘要

1961年至1979年的18年间,得克萨斯大学加尔维斯顿医学分校收治了22例鼻中隔癌患者。18例(82%)为鼻中隔鳞状细胞癌,还有1例网状细胞肉瘤、1例基底细胞癌、1例组织细胞淋巴瘤和1例移行细胞癌。鳞状细胞癌组中有1例在诊断时可触及颈部转移,另有8例患者在治疗后3至25个月出现颈部转移性疾病。鼻中隔鳞状细胞癌具有侵袭性,且常常治疗不足。我们的经验表明,任何大小的鼻中隔癌患者均应接受广泛手术切除(经鼻侧切开术),并对原发部位和颈部进行放疗。18例患者中有17例实现了原发肿瘤的控制,10例患者实现了颈部控制。鼻中隔鳞状细胞癌的五年绝对生存率为66%。

相似文献

1
Carcinoma of the nasal septum.鼻中隔癌
Arch Otolaryngol. 1984 Nov;110(11):748-51. doi: 10.1001/archotol.1984.00800370050012.
2
Nasal septal squamous cell carcinoma: a chart review and meta-analysis.鼻中隔鳞状细胞癌:一项病例回顾与荟萃分析
Laryngoscope. 1996 Oct;106(10):1218-22. doi: 10.1097/00005537-199610000-00008.
3
Squamous cell carcinoma of nasal septum.
J Pak Med Assoc. 1986 Oct;36(10):269-70.
4
Surgical rescue of recurrent carcinoma of the nasal columella.鼻小柱复发性癌的手术挽救治疗
Am J Surg. 1995 Nov;170(5):453-6. doi: 10.1016/s0002-9610(99)80328-6.
5
Carcinoma of the nose and nasal septum: treatment and reconstruction.鼻及鼻中隔癌:治疗与重建
Trans Am Acad Ophthalmol Otolaryngol. 1969 Nov-Dec;73(6):1178-83.
6
[Surgical management of nasal septum malignant tumor].
Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2005 Jul;19(14):636-7.
7
[Epidermoid carcinoma of the nasal septum].鼻中隔表皮样癌
Acta Otorrinolaringol Esp. 1998 Apr;49(3):195-9.
8
Surgical treatment for intranasal squamous cell carcinoma.
AORN J. 1996 Jan;63(1):163-75; quiz 176, 179, 181-2. doi: 10.1016/s0001-2092(06)63451-0.
9
[Squamous cell carcinoma originating from the nasal septum: a case report].[鼻中隔起源的鳞状细胞癌:一例报告]
Kulak Burun Bogaz Ihtis Derg. 2006;16(2):91-3.
10
Long-term radiotherapy outcomes for nasal cavity and septal cancers.鼻腔和鼻中隔癌的长期放疗结果。
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):401-6. doi: 10.1016/j.ijrobp.2007.10.031. Epub 2007 Dec 31.

引用本文的文献

1
Impact of anatomic origin of primary squamous cell carcinomas of the nasal cavity and ethmoidal sinus on clinical outcome.鼻腔和筛窦原发性鳞状细胞癌的解剖学起源对临床结局的影响。
Eur Arch Otorhinolaryngol. 2018 Sep;275(9):2363-2371. doi: 10.1007/s00405-018-5068-3. Epub 2018 Jul 19.
2
Long-term radiotherapy outcomes for nasal cavity and septal cancers.鼻腔和鼻中隔癌的长期放疗结果。
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):401-6. doi: 10.1016/j.ijrobp.2007.10.031. Epub 2007 Dec 31.
3
Squamous cell carcinoma of the nasal columella: a retrospective study of 66 cases from the GETTEC.
鼻小柱鳞状细胞癌:GETTEC的66例回顾性研究。
Eur Arch Otorhinolaryngol. 2008 Jan;265(1):35-41. doi: 10.1007/s00405-007-0503-x. Epub 2007 Oct 26.